Alpha Profiles · Company Profile

ASCENTAGE PHARMA GROUP INTERNATIONAL

Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development.

https://registry.alpha.ac/companies/ascentage-pharma-group-international

Entity: Public listing published
Primary listing: NASDAQ: AAPG
Verification: Partially verified
Last reviewed: 2026-09-18T04:45:57.425698+00:00

Overview

Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I muta

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

4 public records

Dajun Yang, M.D., Ph.D.

Chairman, Chief Executive Officer and Director

Board chairIndependence not stated

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001213900-26-049412Apr 29, 2026

Thomas J. Knapp

SVP, General Counsel

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001213900-26-049412Apr 29, 2026

Veet Misra, Ph.D.

Chief Financial Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001213900-26-049412Apr 29, 2026

Yifan Zhai, M.D., Ph.D.

Chief Medical Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001213900-26-049412Apr 29, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 18, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.